ATE478664T1 - Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren - Google Patents

Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren

Info

Publication number
ATE478664T1
ATE478664T1 AT01986053T AT01986053T ATE478664T1 AT E478664 T1 ATE478664 T1 AT E478664T1 AT 01986053 T AT01986053 T AT 01986053T AT 01986053 T AT01986053 T AT 01986053T AT E478664 T1 ATE478664 T1 AT E478664T1
Authority
AT
Austria
Prior art keywords
azaphenanthridone
derivatives
parp inhibitors
compounds
parp
Prior art date
Application number
AT01986053T
Other languages
English (en)
Inventor
Dana Ferraris
Jia-He Li
Vincent Kalish
Jie Zhang
Original Assignee
Eisai Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Inc filed Critical Eisai Inc
Application granted granted Critical
Publication of ATE478664T1 publication Critical patent/ATE478664T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/06—Peri-condensed systems
AT01986053T 2000-12-01 2001-11-30 Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren ATE478664T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25013200P 2000-12-01 2000-12-01
US31027401P 2001-08-07 2001-08-07
PCT/US2001/044815 WO2002044183A2 (en) 2000-12-01 2001-11-30 Benzoazepine and benzodiazepine derivatives and their use as parp inhibitors

Publications (1)

Publication Number Publication Date
ATE478664T1 true ATE478664T1 (de) 2010-09-15

Family

ID=26940622

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01986053T ATE478664T1 (de) 2000-12-01 2001-11-30 Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren

Country Status (10)

Country Link
US (5) US6887996B2 (de)
EP (1) EP1339402B1 (de)
JP (1) JP4323802B2 (de)
AT (1) ATE478664T1 (de)
AU (1) AU3652102A (de)
CA (1) CA2430363C (de)
DE (1) DE60142921D1 (de)
ES (1) ES2354249T3 (de)
MX (1) MXPA03004832A (de)
WO (1) WO2002044183A2 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60142921D1 (de) 2000-12-01 2010-10-07 Eisai Inc Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren
US7247641B2 (en) * 2001-08-07 2007-07-24 Mgi Gp, Inc. Compounds, derivatives, compositions, preparation and uses
US8563592B2 (en) 2001-11-01 2013-10-22 Spectrum Pharmaceuticals, Inc. Bladder cancer treatment and methods
ES2384208T3 (es) 2001-11-01 2012-07-02 Spectrum Pharmaceuticals, Inc. Composiciones medicinales para el tratatamiento intravesical del cáncer de vejiga.
AU2003201573B2 (en) * 2002-01-22 2009-02-26 Biomatera Inc. Method of drying biodegradable polymers
EP1558253A4 (de) * 2002-10-30 2007-07-25 Merck & Co Inc Piperidinyl-alpha-aminoamid-modulatoren derchemokin-rezeptor-aktivität
SI1585749T1 (sl) 2003-01-09 2008-10-31 Pfizer Derivati diazepinoindola kot inhibitorji kinaze
US20050192321A1 (en) * 2003-09-15 2005-09-01 Meythaler Jay M. Treatment of neuropathy with rapid release aminopyridine
US7399765B2 (en) 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
US20050171079A1 (en) * 2004-02-04 2005-08-04 Schrimpf Michael R. Amino-substituted tricyclic derivatives and methods of use
US7365193B2 (en) 2004-02-04 2008-04-29 Abbott Laboratories Amino-substituted tricyclic derivatives and methods of use
AU2006230582A1 (en) * 2005-03-31 2006-10-05 Spectrum Pharmaceuticals, Inc. Indoloquinone tumor radiation sensitization
US20070023994A1 (en) * 2005-08-01 2007-02-01 Xerox Corporation Media registration systems and methods
BRPI0614168A2 (pt) * 2005-08-05 2017-07-25 Astrazeneca Ab Composto ou um sal, hidrato, solvato, isoforma, tautômero, isômero óptico farmaceuticamente aceitável ou uma combinação dos mesmos, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psquiátricos, uso de um composto, e, processo para a preparação de um composto
WO2007051119A1 (en) * 2005-10-26 2007-05-03 Mgi Gp, Inc. Methods and compositions of parp inhibitors as potentiators in cancer therapy
KR20160067985A (ko) 2005-11-08 2016-06-14 버텍스 파마슈티칼스 인코포레이티드 Ａｔｐ 결합 카세트 수송체의 헤테로사이클릭 조정제
CA2661842C (en) * 2006-09-01 2017-08-22 Cylene Pharmaceuticals, Inc. Tricyclic heteroaryl compounds and their use as serine-threonine protein kinases and parp modulators
CN104447716A (zh) 2007-05-09 2015-03-25 沃泰克斯药物股份有限公司 Cftr调节剂
EP3683218A1 (de) 2007-12-07 2020-07-22 Vertex Pharmaceuticals Incorporated Feste formen von 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioxol-5-yl)-cyclopropancarboxamido)-3-methylpyridin-2-yl)benzoesäure
EP2639224B1 (de) 2007-12-07 2016-08-24 Vertex Pharmaceuticals Incorporated Verfahren zur Herstellung von Cycloalkylcarboxamidopyridinbenzoesäuren
DE602008004820D1 (de) 2007-12-18 2011-03-17 Meiji Seika Kaisha Vorbeuge- oder heilmittel für entzündliche darmerkrankungen
NZ602030A (en) 2008-02-28 2014-02-28 Vertex Pharma Heteroaryl derivatives as cftr modulators
ES2401550T3 (es) * 2008-02-28 2013-04-22 Merck Patent Gmbh Inhibidores de proteína cinasa y uso de los mismos
GB0804755D0 (en) * 2008-03-14 2008-04-16 Angeletti P Ist Richerche Bio Therapeutic compounds
KR101653707B1 (ko) 2008-05-29 2016-09-02 알바니 몰레큘라 리써치, 인크. 5-ｈｔ3 수용체 조절제, 이의 제조 방법, 및 그의 용도
JP2012512246A (ja) 2008-12-17 2012-05-31 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ環修飾型三環式ベンゾナフチリジノン・タンパク質キナーゼ阻害薬及びこれらの使用
US7928105B2 (en) 2009-01-23 2011-04-19 Takeda Pharmaceutical Company Limited Substituted 6a,7,8,9-tetrahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazin-6(5H)-ones
US8541417B2 (en) 2009-07-30 2013-09-24 Takeda Pharmaceutical Company Limited Poly (ADP-ribose) polymerase (PARP) inhibitors
CA2795804C (en) 2010-04-07 2021-10-26 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
WO2011141909A2 (en) 2010-05-10 2011-11-17 Radikal Therapeutics Inc. Lipoic acid and nitroxide derivatives and uses thereof
WO2011145669A1 (ja) * 2010-05-19 2011-11-24 大日本住友製薬株式会社 アミド誘導体
EP2582847B1 (de) 2010-06-18 2016-10-26 Myriad Genetics, Inc. Verfahren und materialien zur bewertung des verlusts der heterozygotie
DK3109325T3 (en) 2010-08-24 2019-01-28 Dana Farber Cancer Inst Inc Methods for predicting anticancer response
GB201106814D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compounds
ES2768344T3 (es) 2011-06-17 2020-06-22 Myriad Genetics Inc Métodos y materiales para evaluar el desequilibrio alélico
JP2014520776A (ja) 2011-07-04 2014-08-25 バイエル・インテレクチユアル・プロパテイー・ゲー・エム・ベー・ハー 植物における非生物的ストレスに対する活性薬剤としての置換されているイソキノリノン類、イソキノリンジオン類、イソキノリントリオン類およびジヒドロイソキノリノン類または各場合でのそれらの塩の使用
DK2794907T4 (da) 2011-12-21 2023-02-27 Myriad Genetics Inc Fremgangsmåder og materialer til vurdering af tab af heterozygositet
EP2797921B1 (de) 2011-12-31 2017-09-06 BeiGene, Ltd. Kondensierte tetra- oder pentacyclische dihydrodiazepincarbazolone als parp-inhibitoren
AU2011384859B2 (en) 2011-12-31 2016-03-17 Beigene, Ltd. Fused tetra or penta-cyclic pyridophthalazinones as PARP inhibitors
AU2013226400B2 (en) 2012-02-23 2018-09-06 Dana-Farber Cancer Institute, Inc. Methods for predicting anti-cancer response
WO2013182645A1 (en) 2012-06-07 2013-12-12 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
WO2014037313A1 (de) * 2012-09-05 2014-03-13 Bayer Cropscience Ag Verwendung substituierter benzodiazepinone und benzazepinone oder deren salze als wirkstoffe gegen abiotischen pflanzenstress
WO2014160080A1 (en) 2013-03-14 2014-10-02 Children's Medical Center Corporation Cancer diagnosis, treatment selection and treatment
EP3693475A1 (de) 2013-04-05 2020-08-12 Myriad Genetics, Inc. Methoden und materialien zur beurteilung eines homologen rekombinationsfehlers
RU2016122882A (ru) 2013-11-12 2017-12-19 Вертекс Фармасьютикалз Инкорпорейтед Способ получения фармацевтических композиций для лечения опосредованных cftr заболеваний
WO2015086473A1 (en) 2013-12-09 2015-06-18 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
ES2946251T3 (es) 2014-08-15 2023-07-14 Myriad Genetics Inc Métodos y materiales para evaluar la deficiencia de recombinación homóloga
CA2968130C (en) 2014-11-18 2022-08-16 Vertex Pharmaceuticals Incorporated Process of conducting high throughput testing high performance liquid chromatography
CN107205993B (zh) * 2014-12-06 2021-03-09 细胞内治疗公司 有机化合物
EP3594343B1 (de) 2015-07-23 2021-04-21 Institut Curie Verwendung einer kombination aus dbait-molekül und parp-inhibitoren zur behandlung von krebs
NZ739876A (en) * 2015-08-25 2022-09-30 Beigene Ltd Process for preparing parp inhibitor, crystalline forms, and uses thereof
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
US9913848B2 (en) * 2016-03-02 2018-03-13 Frequency Therapeutics, Inc. Methods for controlled proliferation of stem cells / generating inner ear hair cells using 1,2,3,4-tetrahydro-[1,4]diazepino[6,7, 1-hi]indolyl based compounds
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
TWI806840B (zh) 2016-09-27 2023-07-01 英屬開曼群島商百濟神州有限公司 使用包含parp抑制劑的組合產品治療癌症
JP6541635B2 (ja) * 2016-10-28 2019-07-10 ベイジーン リミテッド Ｐａｒｐ阻害剤としての縮合四環式または縮合五環式ジヒドロジアゼピノカルバゾロン
KR20190104359A (ko) 2016-12-30 2019-09-09 프리퀀시 테라퓨틱스, 인크. 줄기/전구체 지지 세포의 자가 재생을 유도하기 위한 1h-피롤-2,5-다이온 화합물 및 이의 사용 방법
TW201840564A (zh) 2017-02-28 2018-11-16 英屬開曼群島商百濟神州有限公司 稠合的四環或五環二氫二氮呯幷哢唑酮的鹽的結晶形式及其用途
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
WO2019175132A1 (en) 2018-03-13 2019-09-19 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
US20220227757A1 (en) 2019-05-14 2022-07-21 Suzhou Four Health Pharmaceuticals Co., Ltd. Quinazoline-2,4-dione derivatives as parp inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
JP7446971B2 (ja) 2020-10-02 2024-03-11 株式会社東芝 磁石材料、永久磁石、回転電機及び車両、並びに磁石材料及び永久磁石の製造方法
EP4141127A1 (de) 2021-08-30 2023-03-01 Zentrum Familiärer Brust- und Eierstockkrebs Universitätsklinik Köln Verfahren zur bewertung des mangels an homologer rekombination in eierstockkrebszellen

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3300499A (en) * 1964-01-27 1967-01-24 Sterling Drug Inc 4-alkyl (or alkenyl)-1, 4-dihydro-1-oxobenzo [f] [1, 7] naphthyridine 2-carboxylic acid derivatives
US3398551A (en) * 1966-10-03 1968-08-27 Carrier Corp Compressor control including pressure equalizer and overpressure means
US3700673A (en) * 1971-02-12 1972-10-24 Morton Norwich Products Inc 3-4-dihydrobenzo(b) (1,7)naphthyridin-1(2h)-ones
US6346536B1 (en) 1997-09-03 2002-02-12 Guilford Pharmaceuticals Inc. Poly(ADP-ribose) polymerase inhibitors and method for treating neural or cardiovascular tissue damage using the same
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US6197785B1 (en) * 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US6635642B1 (en) * 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US6121278A (en) 1997-09-03 2000-09-19 Guilford Pharmaceuticals, Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
US20020022636A1 (en) 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
US6395749B1 (en) 1998-05-15 2002-05-28 Guilford Pharmaceuticals Inc. Carboxamide compounds, methods, and compositions for inhibiting PARP activity
JP2002515490A (ja) * 1998-05-15 2002-05-28 ギルフォード ファーマシューティカルズ インコーポレイテッド Ｐａｒｐ活性を抑制する縮合三環化合物
US6380193B1 (en) 1998-05-15 2002-04-30 Guilford Pharmaceuticals Inc. Fused tricyclic compounds, methods and compositions for inhibiting PARP activity
US6201020B1 (en) 1998-12-31 2001-03-13 Guilford Pharmaceuticals, Inc. Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp
US6387902B1 (en) 1998-12-31 2002-05-14 Guilford Pharmaceuticals, Inc. Phenazine compounds, methods and pharmaceutical compositions for inhibiting PARP
KR100632079B1 (ko) 1999-01-11 2006-10-04 아구론 파마슈티컬스, 인크. 폴리(ａｄｐ-리보오스) 중합 효소의 트리사이클릭 저해제
DE59903391D1 (de) * 1999-01-27 2002-12-19 Leica Geosystems Ag Vermessungsgerät mit einer Höhenmesseinrichtung
JP2003510328A (ja) * 1999-09-28 2003-03-18 ビーエーエスエフ アクチェンゲゼルシャフト アゼピノインドール誘導体、その製法ならびに使用
US6348475B1 (en) 2000-06-01 2002-02-19 Guilford Pharmaceuticals Inc. Methods, compounds and compositions for treating gout
FR2816942B1 (fr) * 2000-11-23 2003-05-09 Sanofi Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
DE60142921D1 (de) 2000-12-01 2010-10-07 Eisai Inc Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren

Also Published As

Publication number Publication date
US20050148575A1 (en) 2005-07-07
US20060003987A1 (en) 2006-01-05
USRE41150E1 (en) 2010-02-23
WO2002044183A2 (en) 2002-06-06
US20030022883A1 (en) 2003-01-30
EP1339402B1 (de) 2010-08-25
DE60142921D1 (de) 2010-10-07
CA2430363A1 (en) 2002-06-06
JP4323802B2 (ja) 2009-09-02
EP1339402A2 (de) 2003-09-03
US20060142266A1 (en) 2006-06-29
US6887996B2 (en) 2005-05-03
MXPA03004832A (es) 2004-05-04
CA2430363C (en) 2010-04-13
JP2004517831A (ja) 2004-06-17
AU3652102A (en) 2002-06-11
US7915280B2 (en) 2011-03-29
WO2002044183A3 (en) 2003-05-22
ES2354249T3 (es) 2011-03-11
US7235557B2 (en) 2007-06-26

Similar Documents

Publication Publication Date Title
ATE478664T1 (de) Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren
SE0101675D0 (sv) Novel composition
ATE430747T1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
TW200610531A (en) Phthalazine derivatives as PARP inhibitors
UA85593C2 (uk) Похідні хіназолінону як інгібітори parp
TW200612950A (en) Quinazolinedione derivatives as PARP inhibitors
IL166271A0 (en) Pyrrolidinedione substituted piperidine phthalazone derivatives and pharmaceutical compositions containing the same
EA200100972A1 (ru) Новые соединения и композиции как ингибиторы протеаз
ATE253545T1 (de) Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren
EA199900373A2 (ru) Фармацевтические композиции
ATE252097T1 (de) N-heterocyclische derivate als nos inhibitoren
CY1107747T1 (el) Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
ATE413388T1 (de) Muskarin antagonisten
ES2243579T3 (es) Derivados de pirazolopirideno.
DE60313350D1 (de) Pyrimidin-2,4-dion-derivate als matrix-metalloproteinase-hemmer
EP1244452A4 (de) Urotensin-ii rezeptorantagonisten
AP2001002188A0 (en) 5HT1 antagonists for antidepressant therapy.
BR0318521A (pt) arilindenopiridinas e arilindenopirimidinas e métodos terapêuticos e profiláticos relacionados
DE60329326D1 (de) Tace inhibitoren
ATE335739T1 (de) Cak inhibitoren und deren verwendungen
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
ATE266029T1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
ATE287416T1 (de) Thrombin inhibitoren
ATE246174T1 (de) Tosylprolin-derivate als thymidylat-synthase inhibitoren
MXPA05006587A (es) Compuestos de tiazol como derivados de antagonistas del receptor de la integrina.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties